Anti-TL1A therapy(Generate Biomedicines)

N/A

Report date: 2025/04/30 14:19:38

Base Information

Drug NameAnti-TL1A therapy(Generate Biomedicines)
Drug Alias NamemAb therapy for ulcerative colitis (Generate Biomedicines)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Tumor necrosis factor superfamily member 15
TargetsTumor necrosis factor superfamily member 15
Therapy Area/IndicationsColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenerate Biomedicines Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenerate Biomedicines Inc
Inactive CompaniesN/A
Active IndicationsColitis, Ulcerative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A